Pacira BioSciences opened higher at $36.48, compared with its previous close of $36.46. In the last trading session, the stock traded between $36.46 and $36.49. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Pacira BioSciences is now worth
$ 64.19
Resulting in a loss of
$ 35.81 (35.81%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
+$0.01 (+0.01%)
Day High
$36.49
Day Low
$36.46
Day Open
$36.48
Prev Close
$36.46
Volume
4,94,877
1W Return
0.12%
1M Return
0.33%
3M Return
49.53%
6M Return
60.36%
1Y Return
51.18%
Market Cap ($ Mn)
1,462
PE Ratio
73.60
PB Ratio
1.53
PEG Ratio
50.41
ROE
0.94%
ROCE
0.72%
EPS (TTM)
$0.71
1 Week
0.12%
1 Month
0.33%
3 Months
49.53%
6 Months
60.36%
9 Months
67.81%
Pacira BioSciences grants 22,700 shares to five new employees
Pacira BioSciences Inc. granted inducement equity awards to five new employees on August 4, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards include 8,500 stock options at $27.62 per share and 14,200 restricted stock units, totaling 22,700 shares. Approved by the People & Compensation Committee without shareholder vote, the awards feature four-year vesting schedules tied to continued employment.
3mo agoPacira BioSciences publishes positive 2-year PCRX-201 gene therapy results
Pacira BioSciences published two-year Phase 1 results for PCRX-201, a gene therapy for knee osteoarthritis, in the Annals of the Rheumatic Diseases. The single-injection treatment was well tolerated and showed exploratory improvements in pain, stiffness, and function across all doses. The company is now advancing to the Phase 2 ASCEND trial, with initial topline results scheduled for release by year-end 2026.
3mo agoUnitedHealthcare provides separate reimbursement for EXPAREL
UnitedHealthcare now provides separate reimbursement for EXPAREL across outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This update enables EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members. With approximately 40 million covered lives, UnitedHealthcare is the largest health insurer in the United States.
4mo agoHC Wainwright reiterates Buy on Pacira BioSciences
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Pacira BioSciences, maintaining a price target of $38. The move signals sustained confidence in the company's value.
4mo agoPacira sells iovera to Zimmer Biomet for up to $140 million
Pacira BioSciences announced the divestiture of its iovera system to Zimmer Biomet for up to $140 million, including $70 million upfront and $70 million in milestones through December 31, 2031. The deal, expected to close in Q3 2026, supports Pacira's 5x30 strategy and balance sheet strengthening.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Pacira BioSciences is now worth
$ 64.19
Resulting in a loss of
$ 35.81 (35.81%)
Note: Past profits do not guarantee future returns.
